Category: Bayer

16 UK biotech companies you should know about

The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the…

Continue Reading 16 UK biotech companies you should know about

Ten NK cell therapy companies to look out for this year

Natural killer (NK) cells are white blood cells that are a part of the body’s defense mechanism. These cells are on the lookout for any kind of disruption in the immune system, and can kill diseased cells like tumor cells. NK cells are being used in clinical applications to treat…

Continue Reading Ten NK cell therapy companies to look out for this year

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Vincerx Pharma, Inc. Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone Vincerx remains on…

Continue Reading Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Bayer’s Menopause Drug Elinzanetant Met Primary Endpoints in Phase 3 Studies

By Pierre Bertrand Bayer said that its menopause drug Elinzanetant met the primary endpoints of its Oasis 1 and 2 Phase 3 studies. When compared with placebo, the drug showed a statistically significant reduction in the frequency and the severity of moderate to severe vasomotor symptoms, also known as hot…

Continue Reading Bayer’s Menopause Drug Elinzanetant Met Primary Endpoints in Phase 3 Studies

CRISPR Therapeutics Highlights Strategic Priorities and

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth. “We had a landmark year in 2023, marked…

Continue Reading CRISPR Therapeutics Highlights Strategic Priorities and

80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Job Category Any CategoryJobInternshipWork from Home Job Type Any Job TypesFull-timePart-timeContractVolunteer Location Any CountryUKCanadaAustraliaPakistanIrelandGermanyUSASwedenNew ZealandMalaysiaRussiaNetherlandDubaiSwitzerlandJapanVietnamItalyDenmarkOnlineGeorgiaLatviaSingaporeChinaNetherlandsIndiaFranceBelgiumBrazilColombiaEuropeEstoniaThailandNorwayNigeriaQatarCambodiaUAESouth KoreaAustriaTurkeyworldwideADB CountriesIndonesiaSaudi Arabia Industry Any Industry athletic apparel and footwear Refugee AgencyAccredited registrarAeronauticsAerospaceAirlineappliance manufacturerArtificial Intelligencearts, entertainment, and recreation sectorAstronomical ResearchAutomationAutomativeAviationBankingBioinformaticsBroadcastingBusiness Administrationcar manufacturingchemicalCivic and Social OrganizationsCivil EngineeringConsumer goodsCreativity and Innovation DevelopmentCyber SecurityDairyingData analyticsDevelopmentDigitale-commerceEducationEducationElectric Power GenerationEnergyEngineeringEngineering Professional…

Continue Reading 80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Achievements, accolades highlight past year at VUMC | VUMC Reporter

  Editor’s note — the following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2023.   Whole-genome sequencing agreement Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies,…

Continue Reading Achievements, accolades highlight past year at VUMC | VUMC Reporter

A super-pangenome of the North American wild grape species | Genome Biology

Alston JM, Sambucci O. Grapes in the world economy. In: Cantu D, Walker MA, editors. The grape genome. Springer International Publishing; 2019. p. 1–24. Google Scholar  Rahemi A, Dodson Peterson JC, Lund KT. Grape rootstocks and related species. Cham: Springer International Publishing; 2022. Walker MA, Heinitz C, Riaz S, Uretsky…

Continue Reading A super-pangenome of the North American wild grape species | Genome Biology

Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Non-Hodgkin lymphoma Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the NHL, historical and forecasted epidemiology as well as the Non-Hodgkin lymphoma market trends in the United States EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. {Delhi, India} To…

Continue Reading Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

ABSTRACT Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology. Methods: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August…

Continue Reading Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Hodgkin Lymphoma Pipeline report…

Continue Reading Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

Waiting for Godot: Europe’s Quest to OK Gene Editing

The European Union has some of the world’s strictest regulations on genetically modified crops. But now it is moving to go around them. Two scientists, Vladimir and Estragon, chat every afternoon in the coffee room next to their lab, venting their frustration at the EU’s delay in unfettering gene editing…

Continue Reading Waiting for Godot: Europe’s Quest to OK Gene Editing

Updated Odronextamab Data from Relapsed/Refractory Diffuse

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…

Continue Reading Updated Odronextamab Data from Relapsed/Refractory Diffuse

A naturally occurring polyacetylene isolated from carrots promotes health and delays signatures of aging

Cell culture conditions Unless otherwise stated, cells were cultured with DMEM (Sigma Aldrich; #D6429) and 4.5 g/l glucose, phenol red, 10% FBS, and 1% penicillin/streptomycin with pH 7.4 and were incubated at 37 °C, 5% CO2, and 95% relative humidity. Wild-type HepG2 (#300198), HEK293 (#300192), and MCF-7 (#300273) were derived from CLS…

Continue Reading A naturally occurring polyacetylene isolated from carrots promotes health and delays signatures of aging

Vertex and CRISPR Therapeutics gain FDA approval for CASGEVY – World’s first sickle cell treatment using CRISPR gene editing technology

Dec 8, 2023 Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease – First-ever approval of a CRISPR-based gene-editing therapy in the U.S. – – Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may…

Continue Reading Vertex and CRISPR Therapeutics gain FDA approval for CASGEVY – World’s first sickle cell treatment using CRISPR gene editing technology

Bio Europe 2023: the highlights

The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with…

Continue Reading Bio Europe 2023: the highlights

Advanced Emerging Techniques for Forensic DNA Analysis: STRs, SNPs, and mtDNA Analysis

Alshehhi A, Almarzooqi A, Alhammadi K, Werghi N, Tay GK, Alsafar H (2023) Advancement in human face prediction using DNA. Genes (Basel) 14:136. doi.org/10.3390/genes14010136 CrossRef  CAS  PubMed  Google Scholar  Amorim A, Fernandes T, Taveira N (2019) Mitochondrial DNA in human identification: a review. PeerJ 7:e7314. doi.org/10.7717/peerj.7314 CrossRef  PubMed Central  PubMed …

Continue Reading Advanced Emerging Techniques for Forensic DNA Analysis: STRs, SNPs, and mtDNA Analysis

Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Market Overview and Report Coverage Anaplastic Large Cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that primarily affects the lymph nodes and skin. It is characterized by the abnormal growth of large cells called anaplastic lymphoma kinase (ALK)-positive or ALK-negative lymphoma cells. The ALCL therapeutics market pertains to…

Continue Reading Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

DNA Sequencing Market Surges: Unraveling the Future

DNA Sequencing Market DNA Sequencing Market Report Scope: This report serves as a genetic roadmap, comprehensively examining the DNA Sequencing Market. From breakthrough technologies and market drivers to regional insights and future trends, the report sheds light on the expansive landscape of DNA sequencing. Stakeholders seeking to decipher the intricacies…

Continue Reading DNA Sequencing Market Surges: Unraveling the Future

Synthetic Biology in Agriculture and Food Market Share, Size and Forecast to 2030 | AgBiome, Agrivida, Arzeda

PRESS RELEASE Published December 4, 2023 “Synthetic Biology in Agriculture and Food Market” New Research Insight Report 2023 | Spread Across 103 Pages Report which provides an in-depth analysis Based on Regions, Applications (Agriculture Industry, Food Industry), and Types (Combinatorial DNA Library, CRISPR/Cas9 Genome Editing, Next-Generation DNA Sequencing, Bioinformatics Technologies)….

Continue Reading Synthetic Biology in Agriculture and Food Market Share, Size and Forecast to 2030 | AgBiome, Agrivida, Arzeda

Decoding Fibroblast Growth Factor Receptor 2 Market Metrics: Market Share, Trends, and Growth Patterns | by Tammyfreeman | Dec, 2023

Market Overview and Report Coverage Fibroblast Growth Factor Receptor 2 (FGFR2) is a protein found on the surface of cells that plays a crucial role in cell growth, division, and differentiation. It is a receptor for fibroblast growth factors (FGFs), which are a group of proteins responsible for controlling various…

Continue Reading Decoding Fibroblast Growth Factor Receptor 2 Market Metrics: Market Share, Trends, and Growth Patterns | by Tammyfreeman | Dec, 2023

Zollinger bio Latest Developer Job Openings

devjobsscanner Post a JobJobsBlog Search Search Advanced options Remote Min. Salary… Min. Date… Sort by… Préparateur ou préparatice de commande CDD Zollinger Bio Port-Valais, Valais, Switzerland 2 weeks agofromlinkedin See offer Bioinformatics Developer III Bio-Rad Laboratories Pleasanton, CA bioinformatics 2 weeks agofromlinkedin See offer BIO C BON – Chef des…

Continue Reading Zollinger bio Latest Developer Job Openings

Year in Review: Follicular Lymphoma

Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma. At the start of 2023, a new option became available with the accelerated approval of mosunetuzumab (Lunsumio) late last year. The first-in-class bispecific monoclonal antibody works…

Continue Reading Year in Review: Follicular Lymphoma

EMBL’s European Bioinformatics Institute (EMBL-EBI) in 2023 | Nucleic Acids Research

Abstract The European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) is one of the world’s leading sources of public biomolecular data. Based at the Wellcome Genome Campus in Hinxton, UK, EMBL-EBI is one of six sites of the European Molecular Biology Laboratory (EMBL), Europe’s only intergovernmental life sciences organisation. This…

Continue Reading EMBL’s European Bioinformatics Institute (EMBL-EBI) in 2023 | Nucleic Acids Research

2023-11-27 | NDAQ:REGN | Press Release

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per µL), confirming results from the landmark BOREAS pivotal trial Dupixent rapidly and significantly improved…

Continue Reading 2023-11-27 | NDAQ:REGN | Press Release

Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

Continue Reading Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

Israel-based Fungit has a mission to feed billions of people around the world

“The global population is growing by a staggering 100 million per year,” explained Fungit Biosolutions. “By the year 2050, the world population is expected to grow by more than 3 billion and exceed 10 billion people. An increase in population directly translates into an immediate increase in demand for food.”…

Continue Reading Israel-based Fungit has a mission to feed billions of people around the world

Whole mitochondrial genome sequencing provides new insights into the phylogeography of loggerhead turtles (Caretta caretta) in the Mediterranean Sea

Andrews S (2010) FastQC: a quality control tool for high throughput sequence data. www.bioinformatics.babraham.ac.uk/projects/fastqc Avise JC (1986) Mitochondrial DNA and the evolutionary genetics of higher animals. Philos Trans R Soc Lond B 312:325–342. doi.org/10.1098/rstb.1986.0011 Article  CAS  Google Scholar  Baker CS, Steel D, Calambokidis J, Falcone E, González-Peral U, Barlow J,…

Continue Reading Whole mitochondrial genome sequencing provides new insights into the phylogeography of loggerhead turtles (Caretta caretta) in the Mediterranean Sea

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Is CRISPR Therapeutics the Best Gene-Editing Stock?

A striking analogy can be drawn between the development of monoclonal antibodies and the emergence of CRISPR-based gene editing. Both technologies took roughly 10 years to transition from the laboratory to the market, and both have transformed the field of human medicine. Since the first Food and Drug Administration (FDA)…

Continue Reading Is CRISPR Therapeutics the Best Gene-Editing Stock?

Phase 3 Trial of Factor XIa Inhibitor Asundexian Halted for Lack of Efficacy

Bayer announced earlier this week it has stopped the OCEANIC-AF phase 3 clinical trial investigating the factor FXIa inhibitor asundexian for the agent’s lack of efficacy compared to apixaban, a factor Xa inhibitor, in patients with atrial fibrillation (AF) at risk for stroke or systemic embolism.1 The decision to halt…

Continue Reading Phase 3 Trial of Factor XIa Inhibitor Asundexian Halted for Lack of Efficacy

GMO Corn Market is expected to reach US$ 384.2 billion by 2030

GMO Corn Market – DataM Intelligence GMO Corn Market Size The Global GMO Corn Market reached US$ 260.1 billion in 2022 and is expected to reach US$ 384.2 billion by 2030 and is expected to grow with a CAGR of 5.0% during the forecast period 2023-2030. The adoption of gene…

Continue Reading GMO Corn Market is expected to reach US$ 384.2 billion by 2030

Bayer study halts, Carmot to IPO, and more

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use,…

Continue Reading Bayer study halts, Carmot to IPO, and more

Asundexian Phase 3 AF Study Halted for Lack of Efficacy

The phase 3 OCEANIC-AF trial of the investigational oral factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy of the drug in comparison with apixaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). This decision is based on the recommendation…

Continue Reading Asundexian Phase 3 AF Study Halted for Lack of Efficacy

Bayer Falls Short in Bid to Beat Eliquis in Afib, But Key Stroke Study Continues

Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. The Bayer drug, asundexian, was…

Continue Reading Bayer Falls Short in Bid to Beat Eliquis in Afib, But Key Stroke Study Continues

Twist Bioscience Corp (TWST) Reports 20% Revenue Growth in Fiscal 2023

Twist Bioscience Corp (NASDAQ:TWST) sees a 20% increase in annual revenue, reaching $245.1 million in Fiscal 2023. Orders rise by 17% year-over-year, signaling strong demand for TWST’s synthetic DNA products. Net loss narrows as the company reduces operating expenses and focuses on a path to profitability. On November 17, 2023,…

Continue Reading Twist Bioscience Corp (TWST) Reports 20% Revenue Growth in Fiscal 2023

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -November 17, 2023 at 09:16 am EST

BOSTON – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent…

Continue Reading Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -November 17, 2023 at 09:16 am EST

Wheat Sequencing: The Pan-Genome and Opportunities for Accelerating Breeding

Abberton M, Batley J, Bentley A, Bryant J, Cai H, Cockram J, Costa de Oliveira A, Cseke LJ, Dempewolf H, De Pace C, Edwards D, Gepts P, Greenland A, Hall AE, Henry R, Hori K, Howe GT, Hughes S, Humphreys M, Lightfoot D, Marshall A, Mayes S, Nguyen HT, Ogbonnaya…

Continue Reading Wheat Sequencing: The Pan-Genome and Opportunities for Accelerating Breeding

Navigating the Future through Innovations in the Cancer Genome Sequencing Market and Industry Forecast, 2023-2032

Cancer Genome Sequencing Report PORTLAND, OREGON, UNITED STATES, November 15, 2023 /EINPresswire.com/ — Allied Market Research published an exclusive report Cancer Genome Sequencing Market, which includes a detailed analysis based on competitors and important market segments (2023-2032). The market scenario is analyzed using Porter’s five forces model. This model explains…

Continue Reading Navigating the Future through Innovations in the Cancer Genome Sequencing Market and Industry Forecast, 2023-2032

Landmark academic-industry partnership harvests human genome “fruits” for research – Nashville Medical News

  By Bill Snyder   The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024. Underway is whole genome sequencing of DNA samples from approximately…

Continue Reading Landmark academic-industry partnership harvests human genome “fruits” for research – Nashville Medical News

Landmark academic-industry partnership harvests human genome “fruits” for research | VUMC Reporter

  by Bill Snyder The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024. Underway is whole genome sequencing of DNA samples from approximately 35,000…

Continue Reading Landmark academic-industry partnership harvests human genome “fruits” for research | VUMC Reporter

Bayer Withdraws Aliqopa From US Market for Lymphoma Treatment

The FDA granted accelerated approval to Aliqopa in September 2017 for the treatment of adults with relapsed follicular lymphoma previously treated with at least two prior systemic therapies. Bayer is voluntarily withdrawing a new drug application for copanlisib (Aliqopa) for the treatment of adults with relapsed follicular lymphoma previously administered…

Continue Reading Bayer Withdraws Aliqopa From US Market for Lymphoma Treatment

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Bayer Launches Investigator-Sponsored Collaborative Studies

By Dan Schell, Chief Editor, Clinical Leader Robert Perkins, MD, VP, Cardiovascular & Renal, Bayer Listen, if you’re going to name your clinical development program MOONRAKER — in all caps — you’re going to get noticed, especially from people like me who know that word only as the title of…

Continue Reading Bayer Launches Investigator-Sponsored Collaborative Studies

Scientists use quantum biology, AI to sharpen

image:  ORNL scientists developed a method that improves the accuracy of the CRISPR Cas9 gene editing tool used to modify microbes for renewable fuels and chemicals production. This research draws on the lab’s expertise in quantum biology, artificial intelligence and synthetic biology view more  Credit: Philip Gray/ORNL, U.S. Dept. of…

Continue Reading Scientists use quantum biology, AI to sharpen

Quantum Biology, AI Enhance Genome Editing Tool

Scientists at Oak Ridge National Laboratory used their expertise in quantum biology, artificial intelligence and bioengineering to improve how CRISPR Cas9 genome editing tools work on organisms like microbes that can be modified to produce renewable fuels and chemicals. CRISPR is a powerful tool for bioengineering, used to modify genetic…

Continue Reading Quantum Biology, AI Enhance Genome Editing Tool

Global Precision Medicine Market Size Demonstrates

New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) — Precision medicine is a new approach to treating and preventing disease that considers each individual’s genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal of precision medicine. According to…

Continue Reading Global Precision Medicine Market Size Demonstrates

2023-11-07 | NDAQ:ARVN | Press Release

– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of 11.1 months in patients with AR…

Continue Reading 2023-11-07 | NDAQ:ARVN | Press Release

The MiSeq’s Cameras And The Economics of DNA Sequencers

I’m fascinated by how much scientific instrumentation costs. Why for example does a MiSeq cost so much more than a high end digital camera? What does it say about our society, that we’ve decided to cost optimize cameras and mobile phones but not DNA sequencers? Cheap DNA sequencers seem like…

Continue Reading The MiSeq’s Cameras And The Economics of DNA Sequencers

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new OCEANIC-AFINA study will enrol patients aged 65 and over with atrial fibrillation (AF) and at high risk of…

Continue Reading Bayer doubles down on Factor XIa with new phase 3 trial

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023 | DNA RNA and Cells

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023 Details Category: DNA RNA and Cells Published on Monday, 06 November 2023 11:15 Hits: 53 -CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose-…

Continue Reading CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023 | DNA RNA and Cells

CRISPR Therapeutics Announces Preclinical Data at the

-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- -CTX320™ led to durable reductions of lipoprotein(a) (Lp(a)) levels in NHPs after a single dose- -Both CTX310™ and CTX320™ were well-tolerated in NHPs at clinically relevant dose levels- -Clinical…

Continue Reading CRISPR Therapeutics Announces Preclinical Data at the

Bayer Initiates Expansion of Phase 3 Study of Asundexian -November 06, 2023 at 04:07 am EST

Bayer AG is one of the world’s leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (49.6%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (37.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous…

Continue Reading Bayer Initiates Expansion of Phase 3 Study of Asundexian -November 06, 2023 at 04:07 am EST

Molecular Diagnostics Rapidly Growing Market Globally

[New York, November 2023] — An insightful market analysis report focusing on the Molecular Diagnostics Market has just been released by StatsNData, serving as a valuable resource for both industry leaders and newcomers. This comprehensive report offers a detailed exploration of the global Molecular Diagnostics market and its subsegments, providing…

Continue Reading Molecular Diagnostics Rapidly Growing Market Globally

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Regeneron Pharmaceuticals, Inc. Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations include the first review of primary endpoint results with longer follow-up from the pivotal trial for linvoseltamab in heavily pre-treated patients with multiple…

Continue Reading Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Regeneron Reports Third Quarter 2023 Financial and Operating Results

Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022 Third quarter 2023 Dupixent® global net sales(recorded by Sanofi) increased 33% to $3.10 billion versus third quarter 2022 Third quarter 2023 U.S. net sales for EYLEA® and EYLEA HD were $1.49 billion, including $43…

Continue Reading Regeneron Reports Third Quarter 2023 Financial and Operating Results

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics AG -Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel…

Continue Reading CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Completion of FDA Advisory

-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the…

Continue Reading CRISPR Therapeutics Announces Completion of FDA Advisory

Merck Announces Third-Quarter 2023 Financial Results

October 26, 2023 6:30 am ET Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 8% KEYTRUDA Sales Grew 17% to…

Continue Reading Merck Announces Third-Quarter 2023 Financial Results

RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

(MENAFN– EIN Presswire) RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s global market reports…

Continue Reading RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

Pharmacogenomics (PGx) Market to Grow at CAGR of 7.0%

Newark, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the USD 6.73 billion in 2020 global pharmacogenomics (PGx) market will reach USD 11.63 billion in 2028. Pharmacogenomics (PGx) studies how individuals’ genetic makeup influences their response to medication treatments. The field of precision medicine, which attempts to treat…

Continue Reading Pharmacogenomics (PGx) Market to Grow at CAGR of 7.0%

DNA Diagnostics Market for Non-Invasive Cancer Detection is poised to reach a projected US$ 51.5 Billion by 2032, according to FMI

The healthcare and genetics industries have seen a major shift because to the DNA diagnostics market, which has completely changed how we identify, treat, and comprehend a wide range of illnesses and ailments. With the development of technology and our understanding of genetics, this quickly expanding industry has expanded to…

Continue Reading DNA Diagnostics Market for Non-Invasive Cancer Detection is poised to reach a projected US$ 51.5 Billion by 2032, according to FMI

Twist Bioscience, Bayer enter agreement on antibody discovery and licensing

Twist Bioscience and Bayer announced that they have signed an antibody discovery, option, and licensing agreement. Under the terms of the deal, Twist’s biopharma division will conduct antibody discovery against drug targets to be determined by Bayer. Twist will receive payments connected with the research and will be additionally eligible…

Continue Reading Twist Bioscience, Bayer enter agreement on antibody discovery and licensing

Google Cloud talks generative AI at HLTH ‘23

In healthcare, AI is the most exciting technology we are working on today. From assisting clinicians with documentation, to streamlining operations, to accelerating medical research, to helping doctors detect diseases earlier, this remarkable technology holds the potential to reshape our world and promote healthier, more fulfilling lives. For the healthcare…

Continue Reading Google Cloud talks generative AI at HLTH ‘23

ncRNA | Free Full-Text | Altered Expression of Vitamin D Metabolism Genes and Circulating MicroRNAs in PBMCs of Patients with Type 1 Diabetes: Their Association with Vitamin D Status and Ongoing Islet Autoimmunity

1. Introduction Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by the degeneration of beta cells, resulting in insulin deficiency [1]. T1DM incidence is strongly associated with vitamin D deficiency, and 1,25(OH)2D3 can potentially prevent islet cell death and enhance insulin production. Several studies suggest that low…

Continue Reading ncRNA | Free Full-Text | Altered Expression of Vitamin D Metabolism Genes and Circulating MicroRNAs in PBMCs of Patients with Type 1 Diabetes: Their Association with Vitamin D Status and Ongoing Islet Autoimmunity

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

Continue Reading Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Phase 3 PULSAR Study: Aflibercept 8 mg Monotherapy for PCV: Robust Efficacy Benefits

(Image Credit: ©Africa Studio – Adobe.Stock.com) Reviewed by Chui Ming Gemmy Cheung, MD A subgroup analysis of the phase 3 PULSAR Trial, which evaluated intravitreal aflibercept 8-mg monotherapy (Eylea, Regeneron Pharmaceuticals) compared to aflibercept 2 mg to treat polypoidal choroidal vasculopathy (PCV), showed robust increases in the best-corrected visual acuity…

Continue Reading Phase 3 PULSAR Study: Aflibercept 8 mg Monotherapy for PCV: Robust Efficacy Benefits

Rapid Growth Forecasted: CRISPR And Cas Genes Market Set To Reach US$ 16 Billion By 2033 X Herald

(MENAFN– Ameliorate Digital Consultancy) It is projected that there will be a significant increase in demand for CRISPR and Cas genes, with a remarkable compound annual growth rate (CAGR) of 20% from 2023 to 2033. Currently, the global market for CRISPR and Cas genes is valued at US$ 2.6 billion,…

Continue Reading Rapid Growth Forecasted: CRISPR And Cas Genes Market Set To Reach US$ 16 Billion By 2033 X Herald

REGENERON AND INTELLIA ANNOUNCE EXPANDED RESEARCH COLLABORATION TO DEVELOP CRISPR-BASED THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND MUSCULAR DISEASES

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research…

Continue Reading REGENERON AND INTELLIA ANNOUNCE EXPANDED RESEARCH COLLABORATION TO DEVELOP CRISPR-BASED THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND MUSCULAR DISEASES

Metastatic Prostate Cancer Market Size in the 7MM was ~USD 6400 million in 2022, Estimates DelveInsight

PRESS RELEASE Published October 3, 2023 “The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics”   The Metastatic Prostate…

Continue Reading Metastatic Prostate Cancer Market Size in the 7MM was ~USD 6400 million in 2022, Estimates DelveInsight

Transforming Healthcare With Generative AI

Generative AI is selling itself to emerge as the new frontier in the horizon for the booming healthcare industry. Highlighting some of the significant developments in this technology space, this article has a few Indian leaders voicing their opinions on exploring Generative AI to progress their businesses and services. Generative…

Continue Reading Transforming Healthcare With Generative AI

Five impactful biotech companies to know in New York

New York – the place where people of all backgrounds come with hopes and dreams of making a better life for themselves – is just recently becoming a life sciences powerhouse, attracting many biotech companies, after a $1 billion public investment in the industry from the City of New York. …

Continue Reading Five impactful biotech companies to know in New York

Regeneron and Intellia Announce Expanded Research

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)…

Continue Reading Regeneron and Intellia Announce Expanded Research

Pangenome analysis provides insight into the evolution of the orange subfamily and a key gene for citric acid accumulation in citrus fruits

Swingle, W. T. & Reece, P. C. In The Citrus Industry, History, World Distribution, Botany, and Varieties, Vol. 1 (eds Reuther, W. et al.) 190–143 (Univ. of California Press, 1967). Morton, C. M. & Telmer, C. New subfamily classification for the Rutaceae. Ann. Mo. Bot. Gard. 99, 620–641 (2014). Article …

Continue Reading Pangenome analysis provides insight into the evolution of the orange subfamily and a key gene for citric acid accumulation in citrus fruits

OpenFold Drug Discovery AI Research Consortium Announces Funding of Large-Scale Protein Data Collection at Prof. Gabriel Rocklin’s Laboratory at Northwestern University

New first-in-class datasets will improve the capabilities of state of the art protein AI models to create new biologic drugs DAVIS, Calif., October 02, 2023–(BUSINESS WIRE)–The OpenFold group, a non-profit artificial intelligence (AI) research consortium of biotech and tech firms whose goal is to develop free and open-source software tools…

Continue Reading OpenFold Drug Discovery AI Research Consortium Announces Funding of Large-Scale Protein Data Collection at Prof. Gabriel Rocklin’s Laboratory at Northwestern University

Odronextamab BLA for Treatment of Relapsed/Refractory

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced…

Continue Reading Odronextamab BLA for Treatment of Relapsed/Refractory

Biotechnology Market expected to Witness a Sustainable Growth over 2021-2031

PRESS RELEASE Published September 27, 2023 New York, Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and…

Continue Reading Biotechnology Market expected to Witness a Sustainable Growth over 2021-2031

CRISPR Therapeutics to Present at the Society for

ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA…

Continue Reading CRISPR Therapeutics to Present at the Society for

Plant Breeding and CRISPR Plants Market 2023-2030 Share, Growth Statistics, Business Strategies, Major Players like Bayer, Syngenta, KWS

The Global Plant Breeding and CRISPR Plants market report furnishes valuable insights into the current market landscape. It highlights significant trends, strategies, and future growth prospects. The report extensively covers market developments and analyzes changing industry dynamics. It meticulously examines market segments and sub-segments, providing a comprehensive understanding of the…

Continue Reading Plant Breeding and CRISPR Plants Market 2023-2030 Share, Growth Statistics, Business Strategies, Major Players like Bayer, Syngenta, KWS

DNA Amplification Market Outlook, Future Trends, Insights,

DNA Amplification Market The latest research report on the worldwide DNA Amplification market offers insights into the changing competitive landscape, forthcoming trends, and potential opportunities. Interviews conducted with DNA Amplification industry investors and stakeholders from the Americas, APAC, and EMEA unveil details concerning significant projects influenced by regulatory conditions, subsidies,…

Continue Reading DNA Amplification Market Outlook, Future Trends, Insights,

The data in our DNA | Opinion

In the two decades since the Human Genome Project was declared finished (if not complete), DNA sequencing technology has advanced to the point where reading whole genomes is becoming routine. In 2003 the cost of sequencing an individual’s complete genome was in the order of millions of dollars, today it’s…

Continue Reading The data in our DNA | Opinion

Non-uniform temporal scaling of developmental processes in the mammalian cortex

Selwood, L. & Woolley, P. A. A timetable of embryonic development, and ovarian and uterine changes during pregnancy, in the stripe-faced dunnart, Sminthopsis macroura (Marsupialia: Dasyuridae). J. Reprod. Fertil. 91, 213–227 (1991). Article  CAS  PubMed  Google Scholar  Sacher, G. A. & Staffeldt, E. F. Relation of gestation time to brain…

Continue Reading Non-uniform temporal scaling of developmental processes in the mammalian cortex

Metagenomics Co Op Job in Missouri

At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where ‘Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around…

Continue Reading Metagenomics Co Op Job in Missouri

Ambrx Biopharma (NYSE:AMAM) vs. CRISPR Therapeutics (NASDAQ:CRSP) Financial Survey

Ambrx Biopharma (NYSE:AMAM – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This…

Continue Reading Ambrx Biopharma (NYSE:AMAM) vs. CRISPR Therapeutics (NASDAQ:CRSP) Financial Survey

Species-specific responses of marine bacteria to environmental perturbation

Worden AZ, Follows MJ, Giovannoni SJ, Wilken S, Zimmerman AE, Keeling PJ. Rethinking the marine carbon cycle: Factoring in the multifarious lifestyles of microbes. Science. 2015;347:1257594–1257594. PubMed  Google Scholar  Moran MA. The global ocean microbiome. Science. 2015;350:aac8455–aac8455. PubMed  Google Scholar  Sunagawa S, Coelho LP, Chaffron S, Kultima JR, Labadie K,…

Continue Reading Species-specific responses of marine bacteria to environmental perturbation

Opening Keynote Offers Hopeful Outlook for Cell and Gene Therapy

By Julianna LeMieux, PhD  The opening keynote of the In Vivo Gene Therapy Manufacturing track at the BioProcess International meeting, taking place this week in Boston, was a riveting kickstart to the meeting. Over two hours, the speakers covered multiple aspects of cell and gene therapy—not only celebrating the triumphs,…

Continue Reading Opening Keynote Offers Hopeful Outlook for Cell and Gene Therapy

Diffuse Large B-cell Lymphoma Market to Show Immense Growth

New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) — Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda The DLBCL market has a diverse pipeline, with the emergence of…

Continue Reading Diffuse Large B-cell Lymphoma Market to Show Immense Growth

Single-cell brain organoid screening identifies developmental defects in autism

Stem cell and cerebral organoid culture conditions Feeder-free hES cells or iPS cells were cultured on hES cell-qualified Matrigel (Corning, catalogue no. 354277)-coated plates with Essential8 stem cell medium supplemented with bovine serum albumin (BSA). H9 embryonic stem cells were obtained from WiCell. Cells were maintained in a 5% CO2 incubator at 37 °C….

Continue Reading Single-cell brain organoid screening identifies developmental defects in autism

Plant Genomics Market Research Report and Report associated with it Reveals the Latest Trends And Opportunities of this market for period from 2023 to 2030.

PRESS RELEASE Published September 13, 2023 List of reports available with us. Plant Breeding and CRISPR Plants Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Plant Wall Systems Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Soil Enhancers Market Size / CAGR / Sales…

Continue Reading Plant Genomics Market Research Report and Report associated with it Reveals the Latest Trends And Opportunities of this market for period from 2023 to 2030.

Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

The “Fibroblast Growth Factor Receptor 2 Market” is focused on controlling cost, and improving efficiency. Moreover, the reports offer both the demand and supply aspects of the market. The Fibroblast Growth Factor Receptor 2 market is expected to grow annually by 7% (CAGR 2023 – 2030). Fibroblast Growth Factor Receptor…

Continue Reading Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

Genetic Testing Market – Top a Valuation of USD 39.2 Bn by

New York, Sept. 11, 2023 (GLOBE NEWSWIRE) — According to Market.us, the Global Genetic Testing Market size is projected to surpass around USD 39.2 billion by 2032, and it is poised to reach a CAGR of 9.7% from 2023 to 2032. Genetic testing is a specialized medical examination designed to detect…

Continue Reading Genetic Testing Market – Top a Valuation of USD 39.2 Bn by

Genome analysis of ST1 Bartonella henselae

Introduction Infective endocarditis (IE), as a disease first recognized in 1885, is defined by infection of a native or prosthetic heart valve, the endocardial surface, or an indwelling cardiac device.1–3 Despite advances in diagnostic capabilities and treatment options, IE remains a rare condition but with high associated mortality. And epidemiological…

Continue Reading Genome analysis of ST1 Bartonella henselae

Allogeneic iPSCs Gaining Momentum Due to Ease of Access and Economies of Scale

While autologous iPSC-based cell therapies are patient-specific, allogeneic iPSC-based cell therapies use donor-derived cells as a starting material. In recent years, a greater number of allogeneic iPSC-derived cell therapies are being studied than autologous therapies. One of the advantages of allogeneic therapy is that a large number of doses can…

Continue Reading Allogeneic iPSCs Gaining Momentum Due to Ease of Access and Economies of Scale

Google extends generative AI leadership at Google Cloud Next

In a theme that is sure to permeate throughout the rest of the fall show season, Google Cloud put its generative AI chops front and center across the most packed set of AI-centric announcements we’ve seen yet in the enterprise technology market. Google Cloud Next 2023 was loaded across…

Continue Reading Google extends generative AI leadership at Google Cloud Next

CRISPR Therapeutics Announces Leadership Transition

-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023–Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company- ZUG, Switzerland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical…

Continue Reading CRISPR Therapeutics Announces Leadership Transition

Google Reshapes the Era of AI and Automation in Healthcare

Google has become a major player in integrating AI and automation in healthcare with its AI-powered solutions, mainly Med-PaLM 2 and Vertex AI. Augmedix Go, an application developed in collaboration with Augmedix, simplifies medical note generation by recording patient conversations, benefiting HCA Healthcare. Bayer Pharma utilizes Med-PaLM 2 and Google…

Continue Reading Google Reshapes the Era of AI and Automation in Healthcare

Details On Bayer’s Partnership With Google Cloud To Integrate Cutting-edge AI Into Its Core Businesses

The company is nearly 150 years old and continues to innovate and expand its global reach and impact with an unwavering commitment to improving patient care. His latest initiatives include his extensive work with AI, notably in collaboration with Google Cloud. September 04, 2023 14:38 Bayer is one of the…

Continue Reading Details On Bayer’s Partnership With Google Cloud To Integrate Cutting-edge AI Into Its Core Businesses